August 2012
-
Windtree Therapeutics has signed an agreement with Hong-Kong based Lee’s Pharmaceutical Limited for the development and commercialization of Aerosurf and other KL4 surfactant products in a number of Asian countries, the company said. Lee’s will… Read more . . .
-
German biotech Ventaleon, a spin-off of Activaero, which was acquired by Vectura in 2014, presented data from a Phase 2 trial of inhaled D, L-lysine acetylsalicylate glycine (LASAG) in severe influenza at the recent ISAM… Read more . . .
-
Smartinhaler manufacturer Adherium Limited has appointed Arik Anderson as Group CEO, the company said. He succeeds company founder Garth Sutherland, who will stay on as an Executive Director on the board. Anderson, who was most… Read more . . .
-
Dr. Reddy’s subsidiary Promius Pharma has announced that a Phase 2 study of its DFN-02 intranasal sumatriptan for the treatment of migraine met its primary endpoint, the proportion of subjects free of migraine pain at… Read more . . .
-
The Grünenthal Group will acquire rights to all dosage forms of Zomig zolmitriptan for the treatment of migraines and cluster headaches, including Zomig nasal spray, from AstraZeneca for $200 million up front plus up to… Read more . . .
-
InCarda Therapeutics has announced that a Phase 1 study of InRhythm inhaled flecainide, which it is developing for the treatment of paroxysmal atrial fibrillation (PAF), met its primary and secondary endpoints, with all doses found… Read more . . .
-
Aptar Pharma has transferred manufacturing equipment for its Child-Resistant and Senior-Friendly Classic Nasal Pump from a plant in Germany to its facility in Congers, NY, the company said. According to Aptar, its child-resistant pump is… Read more . . .
-
Egalet Corporation has announced that Ascend Therapeutics will begin co-promoting Egalet’s Sprix ketorolac tromethamine nasal spray to women’s healthcare practitioners in the US in the third quarter of 2017 and will continue for at least… Read more . . .
-
Device company Nemera has announced a partnership with the Research Center for Respiratory Diseases (CEPR) at the University of Tours for investigation of a novel intranasal drug delivery method. Nemera, which was formerly known as… Read more . . .
-
Anyone wishing to enter the competition for the new DDL Emerging Scientist award should submit their CV and a 1000-word synopsis of their work by June 30, 2017. The winner will present the DDL Emerging… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland